Baliga Lab researchers and collaborators found that genetic program activity delineates risk, relapse, and therapy responsiveness in multiple myeloma

Posted Posted in News

ISB researchers Drs. Matt Wall, Serdar Turkarslan, Nitin Baliga, and others, along with collaborators, have developed a technology to generate a patient-specific disease-relevance network map to accurately predict risk, personalize therapies, and discover novel drug targets for solid and liquid tumors.